Trial Profile
A randomised, double-blind, placebo-controlled, dose ascending crossover study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of inhaled GSK159797 delivered by dry powder inhaler in mild to moderate asthmatic subjects.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Milveterol (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 29 Sep 2006 New trial record.